Researchers from the Indian Institute of Technology (IIT-BHU) and the Institute of Medical Sciences (IMS), BHU, have developed a novel nature-inspired protein-fenugreek-based biomaterial for the treatment of deep muscle wounds and skin photoprotection.
This cutting-edge technology is now rapidly progressing towards clinical trials.
The research project was led by Dr. Avneesh Singh Parmar (IIT-BHU) and Prof. Vaibhav Jain (IMS-BHU). The bio-composite material, developed and patented by the team, accelerates tissue regeneration, protects the skin from harmful ultraviolet (UV) rays, and also possesses potent antimicrobial properties.
Dr. Parmar explained that diabetic wounds do not heal quickly. This research will prove very effective in the treatment of diabetic wounds in the coming days.
This technology was presented at the UP Health Tech Conclave 1.0 on January 20, 2026, further strengthening its potential for effective use at the state and national levels. This achievement is a significant step towards the development of sustainable and bio-inspired medical solutions and underscores IIT (BHU)’s commitment to socially relevant research.
Expressing his delight at this achievement, Prof. Amit Patra, Director of IIT (BHU), said here on Tuesday that, “This research work is an excellent example of the high-level translational research being conducted at IIT-BHU. This development of a nature-inspired biomaterial will not only open new possibilities in the medical field but also demonstrates that our scientists are focused on innovation to solve real-world problems of society. We are proud that this technology is now moving towards clinical trials.”
Young researchers played a crucial role in the development of this innovation, including Shikha Tripathi (PMRF Fellow, IIT-BHU) and Dr. Shilpi Chaudhary (PEC, Chandigarh).
Pre-clinical studies conducted on rat and rabbit models have confirmed rapid healing of deep muscle wounds, excellent biocompatibility, and the absence of any toxicity.
The process of submitting it to the Central Drugs Standard Control Organization (CDSCO) for initiating human clinical trials is underway.
Considering its commercial and social significance, the research team has established a startup called ‘Pro-Amyloidocare Private Limited,’ which is incubated at I3F, IIT (BHU). This startup has received financial support under the IIT (BHU) Foundation and the JIC Startup Award.